Kosuke Ashihara
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Kosuke Ashihara has a total of 23 co-authors. Here are the top co-authors by number of shared publications:
- Satoshi Okada
Department of Pediatrics, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan
2 shared publications - Takaki Asano
Graduate School of Biomedical and Health Sciences, Hiroshima University 1 Department of Pediatrics Hiroshima
2 shared publications - Takanori Utsumi
Graduate School of Biomedical and Health Sciences, Hiroshima University 1 Department of Pediatrics Hiroshima
2 shared publications - Chiaki Tao
Hiroshima University Graduate School of Biomedical and Health Sciences 7 Department of Pediatrics Hiroshima
1 shared publication - Dusan Bogunovic
Center for Genetic Errors of Immunity, Columbia University 3 Department of Pediatrics New York, NY
1 shared publication - Fumiaki Sakura
Hiroshima University Graduate School of Biomedical & Health Sciences 3 Department of Pediatrics Hiroshima
1 shared publication
Latest Publications
- Open Access
- 16 September 2026
- Published by Rockefeller University Press in Journal of Human Immunity
- Vol. 2 (6)
High prevalence of autoantibodies neutralizing type I IFNs in Japanese patients with hepatitis C
Autoantibodies neutralizing type I IFNs (AAN-I-IFNs) are being identified as major, common, and global determinants of a growing range of severe viral diseases. We examined whether persistent hepatitis C virus (HCV) infection, with or without IFN-α therapy, could induce AAN-I-IFNs. We tested 2,573 HCV patients aged 1–95 years (1,115 treated with IFN-α, 1,458 untreated) and 1,000 healthy controls. AAN-INF-α2 prevalence was significantly higher in hepatitis C patients (2.7%) than in healthy controls (0.7%) and was higher still in those treated with IFN-α (3.9%) than in untreated patients (1.9%) (P = 0.0053). A longitudinal study of 15 IFN-α–treated patients with AAN-IFN-α2 revealed that only one had AAN-IFN-α2 before IFN-α therapy and that 12 patients developed AAN-IFN-α2 in the year following treatment. However, 80% eventually became AAN-IFN-α2 negative. These findings suggest that chronic HCV infection, perhaps due to the chronic production of endogenous IFN-α, and exogenous IFN-α treatment promote the development of AAN-IFN-α2.
- 16 September 2026
- Published by Rockefeller University Press in Journal of Human Immunity
- Vol. 2 (6)
Open AccessHigh prevalence of autoantibodies neutralizing type I IFNs in Japanese patients with hepatitis C
Autoantibodies neutralizing type I IFNs (AAN-I-IFNs) are being identified as major, common, and global determinants of a growing range of severe viral diseases. We examined whether persistent hepatitis C virus (HCV) infection, with or without IFN-α therapy, could induce AAN-I-IFNs. We tested 2,573 HCV patients aged 1–95 years (1,115 treated with IFN-α, 1,458 untreated) and 1,000 healthy controls. AAN-INF-α2 prevalence was significantly higher in hepatitis C patients (2.7%) than in healthy controls (0.7%) and was higher still in those treated with IFN-α (3.9%) than in untreated patients (1.9%) (P = 0.0053). A longitudinal study of 15 IFN-α–treated patients with AAN-IFN-α2 revealed that only one had AAN-IFN-α2 before IFN-α therapy and that 12 patients developed AAN-IFN-α2 in the year following treatment. However, 80% eventually became AAN-IFN-α2 negative. These findings suggest that chronic HCV infection, perhaps due to the chronic production of endogenous IFN-α, and exogenous IFN-α treatment promote the development of AAN-IFN-α2.
- Open Access
- 4 February 2026
- Published by Rockefeller University Press in Journal of Human Immunity
- Vol. 2 (2)
Acute necrotizing encephalopathy associated with COVID-19 in a pediatric patient and a systematic review
Coronavirus disease 2019 (COVID-19), caused by SARS-CoV-2, can lead to neurological complications such as acute necrotizing encephalopathy (ANE). However, the pathogenesis of ANE associated with COVID-19 remains unclear. We report a case of ANE associated with COVID-19 and then conducted a literature review using PubMed for cases reported up to June 30, 2024. Clinical data from 74 patients were analyzed. Among those with severe sequelae (n = 28), 39.2% (n = 11) had hemorrhagic findings on CT or MRI, significantly more than in the mild sequelae group (10.8% [n = 5], P = 0.04). 16 patients underwent genetic testing for RANBP2 mutations, of whom four (25%, n = 16) tested positive. These findings suggest that imaging evidence of hemorrhage may be a poor prognostic factor and that RANBP2 mutations could contribute to disease susceptibility. Further genetic studies involving larger cohorts are needed to better understand the mechanisms of ANE associated with COVID-19 and improve outcomes for affected patients.
- 4 February 2026
- Published by Rockefeller University Press in Journal of Human Immunity
- Vol. 2 (2)
Open AccessAcute necrotizing encephalopathy associated with COVID-19 in a pediatric patient and a systematic review
Coronavirus disease 2019 (COVID-19), caused by SARS-CoV-2, can lead to neurological complications such as acute necrotizing encephalopathy (ANE). However, the pathogenesis of ANE associated with COVID-19 remains unclear. We report a case of ANE associated with COVID-19 and then conducted a literature review using PubMed for cases reported up to June 30, 2024. Clinical data from 74 patients were analyzed. Among those with severe sequelae (n = 28), 39.2% (n = 11) had hemorrhagic findings on CT or MRI, significantly more than in the mild sequelae group (10.8% [n = 5], P = 0.04). 16 patients underwent genetic testing for RANBP2 mutations, of whom four (25%, n = 16) tested positive. These findings suggest that imaging evidence of hemorrhage may be a poor prognostic factor and that RANBP2 mutations could contribute to disease susceptibility. Further genetic studies involving larger cohorts are needed to better understand the mechanisms of ANE associated with COVID-19 and improve outcomes for affected patients.